Tag: Healthcare/Life Sciences

As investors question the validity of ESG ratings, some are looking to public-benefit corporations instead.

The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity.

Shares of Recursion Pharmaceuticals, Schrodinger and others that are implementing AI are surging.

Biogen, Eli Lilly drugs will expand the imaging market for companies in the diagnostics space.

Healthcare and financial stocks this week pushed into positive territory for the year.

The activist is pushing for a shake-up of the contract drug manufacturer’s board.

Roivant, started by presidential candidate Vivek Ramaswamy, could seal a deal in coming days.

The money manager GMO, co-founded by Jeremy Grantham, bets on cheap stocks and bonds backed by commercial real estate.

The potential FDA approval of BioMarin’s gene therapy for hemophilia A would be a major win, but patient uptake could ...

Developers of Alzheimer’s drugs have work cut out for them getting the treatments to patients.